The studies behind the science.

The first placebo-controlled trial of ketamine for depression. A single infusion produced rapid improvement in mood within hours — the finding that kicked off three decades of research into ketamine as an antidepressant.

The landmark NIMH-led trial that established ketamine's rapid antidepressant effect in a controlled setting — improvement within two hours, sustained for about a week after a single dose.

A larger, multi-site trial (n=73) comparing ketamine to an active placebo (midazolam), addressing earlier criticisms about study size and blinding — and confirming ketamine's rapid effect held up under stricter conditions.

Pooled data across multiple trials showing a single ketamine infusion significantly reduced suicidal ideation compared to placebo — one of the most cited papers on ketamine's anti-suicidal effects.

A randomized trial of intranasal esketamine showing a significant, dose-dependent improvement in depressive symptoms — part of the clinical package that led to esketamine's FDA approval.

One of the pivotal Phase 3 trials for esketamine, showing statistically significant improvement over an oral antidepressant alone — a key piece of evidence behind its regulatory approval.

An influential review from some of the field's leading researchers, describing ketamine as the first exemplar of a genuinely new, rapid-acting approach to treating depression — and what its success reveals about the biology of the disorder itself.

The regulatory milestone: the first NMDA-receptor-targeting antidepressant approved by the FDA in decades, based on the clinical trial data above — a major turning point for ketamine-based treatment reaching patients.